Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Gatehouse Bio is raising $5,445,379.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Salzman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gatehouse Bio

At Gatehouse Bio, we ask bold questions. Our sRNA platform lets us act on opportunities everywhere. In the dark area of the genome, In the unseen connection of disease pathways, In the novel uses of existing compounds. For our partners, these opportunities have the power to transform their business. For patients, they have the power to transform their lives.

To learn more about Gatehouse Bio, visit http://gatehousebio.com/

Contact:
David Salzman, Chief Executive Officer
339-707-7763
https://www.linkedin.com/in/david-w-salzman-44515b4a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved